PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-κBp65/mTOR-dependent mechanism

被引:138
作者
Vinciguerra, Manlio [1 ]
Veyrat-Durebex, Christelle [2 ]
Moukil, Moulay Ahmed [1 ]
Rubbia-Brandt, Laura [3 ]
Rohner-Jeanrenaud, Francoise [2 ]
Foti, Michelangelo [1 ]
机构
[1] Univ Hosp Geneva, Geneva Med Fac, Dept Cell Physiol & Metab, Geneva, Switzerland
[2] Univ Hosp Geneva, Dept Internal Med, Geneva, Switzerland
[3] Univ Hosp Geneva, Div Clin Pathol, Geneva, Switzerland
关键词
D O I
10.1053/j.gastro.2007.10.010
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a tumor suppressor and a regulator of insulin sensitivity in peripheral tissues. In the liver, PTEN deletion increases insulin sensitivity, but induces steatosis, steatohepatitis, and hepatocellular carcinoma. Here, we investigated the pathophysiologic mechanisms regulating PTEN expression in the liver and the development of steatosis. Methods: PTEN expression was evaluated in the liver of rats and human beings having metabolic syndrome. Signaling pathways regulating PTEN expression and lipid accumulation in hepatocytes were examined in vitro. Results: PTEN expression is down-regulated in the liver of rats having steatosis and high plasma levels of fatty acids, as well as in steatotic human livers. Unsaturated fatty acids inhibited PTEN expression in HepG2 cells via activation of a signaling complex formed by the mammalian target of rapamycin (mTOR) and nuclear factor-kappa B (NF-kappa B). Down-regulation of PTEN expression induced steatosis by affecting import, esterification, and extracellular release of fatty acids. Conclusions: Hepatic steatosis can be mediated by alterations of PTEN expression in hepatocytes exposed to high levels of unsaturated fatty acids. Furthermore, our data revealed interaction between mTOR and NF-kappa B, suggesting cross-talk between these 2 pathways.
引用
收藏
页码:268 / 280
页数:13
相关论文
共 33 条
[1]   FoxO1 stimulates fatty acid uptake and oxidation in muscle cells through CD36-dependent and -independent mechanisms [J].
Bastie, CC ;
Nahlé, Z ;
McLoughlin, T ;
Esser, K ;
Zhang, WW ;
Unterman, T ;
Abumrad, NA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (14) :14222-14229
[2]   Impact of mitochondrial β-oxidation in fatty acid-mediated inhibition of glioma cell proliferation [J].
Berge, K ;
Tronstad, KJ ;
Bohov, P ;
Madsen, L ;
Berge, RK .
JOURNAL OF LIPID RESEARCH, 2003, 44 (01) :118-127
[3]   Interleukin-18 induces human cardiac endothelial cell death via a novel signaling pathway involving NF-κB-dependent PTEN activation [J].
Chandrasekar, B ;
Valente, AJ ;
Freeman, GL ;
Mahimainathan, L ;
Mummidi, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 339 (03) :956-963
[4]   PTEN function in normal and neoplastic growth [J].
Chow, Lionel M. L. ;
Baker, Suzanne J. .
CANCER LETTERS, 2006, 241 (02) :184-196
[5]   The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence [J].
El-Serag, HB ;
Hampel, H ;
Javadi, F .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (03) :369-380
[6]   Nonalcoholic fatty liver disease: From steatosis to cirrhosis [J].
Farrell, GC ;
Larter, CZ .
HEPATOLOGY, 2006, 43 (02) :S99-S112
[7]   Impact of the liver-specific expression of SHIP2 (SH2-containing inositol 5′-phosphatase 2) on insulin signaling and glucose metabolism in mice [J].
Fukui, K ;
Wada, T ;
Kagawa, S ;
Nagira, K ;
Ikubo, M ;
Ishihara, H ;
Kobayashi, M ;
Sasaoka, T .
DIABETES, 2005, 54 (07) :1958-1967
[8]   Regulation of the PTEN phosphatase [J].
Gericke, Arne ;
Munson, Mary ;
Ross, Alonzo H. .
GENE, 2006, 374 :1-9
[9]   Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas [J].
Horie, Y ;
Suzuki, A ;
Kataoka, E ;
Sasaki, T ;
Hamada, K ;
Sasaki, J ;
Mizuno, K ;
Hasegawa, G ;
Kishimoto, H ;
Iizuka, M ;
Naito, M ;
Enomoto, K ;
Watanabe, S ;
Mak, TW ;
Nakano, T .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (12) :1774-1783
[10]   Serine 202 regulates the nuclear translocation of constitutive active/androstane receptor [J].
Hosseinpour, F ;
Moore, R ;
Negishi, M ;
Sueyoshi, T .
MOLECULAR PHARMACOLOGY, 2006, 69 (04) :1095-1102